Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study.

Mult Scler 2019 03 24;25(3):399-407. Epub 2018 Jan 24.

Multiple Sclerosis Study Center, Gallarate Hospital, ASST Valle Olona, Via Eusebio Pastori 4, 21013 Gallarate, Italy.

Background: Few data are available on very long-term follow-up of pediatric multiple sclerosis (MS) patients treated with disease modifying treatments (DMTs).

Objectives: To present a long-term follow-up of a cohort of Pediatric-MS patients starting injectable first-line agents.

Methods: Data regarding treatments, annualized relapse rate (ARR), Expanded Disability Status Scale (EDSS) score, and serious adverse event were collected. Baseline characteristics were tested in multivariate analysis to identify predictors of disease evolution.

Results: In total, 97 patients were followed for 12.5 ± 3.3 years. They started therapy at 13.9 ± 2.1 years, 88 with interferons and 9 with copaxone. During the whole follow-up, 82 patients changed therapy, switching to immunosuppressors/second-line treatment in 58% of cases. Compared to pre-treatment phase, the ARR was significantly reduced during the first treatment (from 3.2 ± 2.6 to 0.7 ± 1.5, p < 0.001), and it remained low during the whole follow-up (0.3 ± 0.2, p < 0.001). At last observation, 40% had disability worsening, but EDSS score remained <4 in 89%. One patient died at age of 23 years due to MS. One case of natalizumab-related progressive multifocal encephalopathy (PML) was recorded. Starting therapy before 12 years of age resulted in a better course of disease in multivariate analysis.

Conclusion: Pediatric-MS patients benefited from interferons/copaxone, but the majority had to switch to more powerful drugs. Starting therapy before 12 years of age could lead to a more favorable outcome.

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458518754364DOI Listing
March 2019
31 Reads

Publication Analysis

Top Keywords

long-term follow-up
12
follow-up pediatric
8
injectable first-line
8
patients starting
8
patients
5
characteristics tested
4
event collected
4
tested multivariate
4
baseline characteristics
4
collected baseline
4
identify predictors
4
disease evolutionresults
4
evolutionresults total
4
predictors disease
4
adverse event
4
analysis identify
4
multivariate analysis
4
scale edss
4
relapse rate
4
rate arr
4

References

(Supplied by CrossRef)

Waldman A et al.
Lancet Neurol 2014

Benson LA et al.
Mult Scler Relat Disord 2014

Gorman MP et al.
Arch Neurol 2009

Renoux C et al.
N Engl J Med 2007

Banwell B et al.
Neurology 2006

Ghezzi A et al.
Neurol Sci 2009

Kornek B et al.
Neuropediatrics 2003

Krupp LB et al.
J Neurol Sci 2016

Mikaeloff Y et al.
Eur J Paediatr Neurol 2008

Mikaeloff Y et al.
J Pediatr 2001

Pohl D et al.
Neurology 2005

Similar Publications